1. Semaglutide and tirzepatide have the highest weight loss efficacy.
2. Metformin may be only safely used in people with an estimated GFR of 45 or greater.
3. Avoid dual GIP and GLP-1 RA therapy in people with gastroparesis.
4. Consider combination therapy in people presenting with A1C levels 1.5–2.0% above goal.

Click Here to Test your Knowledge

---

Want to learn more about this question?

Meds Management Update for Type 2 Diabetes

Airs live on December 21st, 2023, at 11:30 am PT

Topics:

• Describe the role of Diabetes Care & Education Specialists in advocating for optimal therapeutic approaches.
• Discuss the application of the new ADA/EASD Guidelines to improve glucose and reduce CV and renal risk.
• List strategies to initiate & adjust oral & injectable therapy using a person-centered approach.

In this exciting webinar, Coach Beverly walks participants through the “Management of Hyperglycemia in Type 2 Diabetes” as outlined by the most recent American Diabetes Association (ADA) guidelines. She kicks-it off with a brief overview of the different classes of medications then uses a case study approach to apply the ADA algorithm.

Can’t make it live? No worries. We will send post the recorded version to the Online University within 24 hours of the broadcast

Instructor: Beverly Thomassian RN, MPH, CDCES, has been Board Certified in Advanced Diabetes Management for over 20 years. She is an Associate Clinical Professor at UCSF, a working educator, and a nationally recognized diabetes expert. She has a Master’s Degree in Public Health from UCLA, with a focus on behavioral health and education.

---

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

---

The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.